Connect with us

Health

January 1, Mayo Clinic Blood Test Shows Promise for Spotting Early Alzheimer’s Risk in Seniors

Published

on

Wyatt’s Take

  • A simple blood test can now flag the protein buildup that signals future memory loss years ahead of time.
  • Researchers say the test could help families make smarter choices if new preventive medicines become available.
  • Until safe treatments exist, routine screening for healthy seniors is still not recommended.

A new Mayo Clinic study shows a blood marker could help doctors estimate whether older Americans will face cognitive decline within five to ten years.

The study followed 2,178 healthy adults between 60 and 90 years old.

Researchers measured levels of phosphorylated tau 217, a protein tied to the brain plaques and tangles that mark Alzheimer’s disease.

They also factored in age, gender, and whether participants carried the APOE ε4 gene variant.

“The test tells you, just by taking a blood sample, whether someone has that pathology in the brain,” said senior author Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist.

Higher levels of the protein were linked to greater odds of slipping from normal memory to mild impairment.

At the same protein level, an 85-year-old faced a 37 percent five-year risk, while a 65-year-old showed only a 6 percent risk.

Researchers say the blood test could one day replace costly PET scans that measure amyloid buildup in the brain.

“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” said first author Alicia Algeciras-Schimnich, Ph.D., in a news release.

“If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment,” Jack noted.

Jack cautioned that the model was built on older adults in southeast Minnesota and may not reflect the whole country.

Further testing in other regions is needed before wider use.

The risk model is not ready for routine screening of healthy people today.

“There is no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain,” Jack told Fox News Digital.

“Therefore, there’s no reason to do the test. … The results of the test would not change your medical management at all since there’s no treatment available.”

Many seniors who carry low levels of the brain pathology may never develop symptoms.

Others may pass away from different causes before memory loss appears.

Wyatt Matters

Hard-working families deserve straightforward tools that help them plan ahead without turning every doctor visit into a costly ordeal. This research moves us closer to practical answers that respect both medical reality and the budgets of everyday Americans.

Leave a Reply

Your email address will not be published. Required fields are marked *

Click to comment


Wyatt Porter is a seasoned writer and constitutional scholar who brings a rugged authenticity and deep-seated patriotism to his work. Born and raised in small-town America, Wyatt grew up on a farm, where he learned the value of hard work and the pride that comes from it. As a conservative voice, he writes with the insight of a historian and the grit of a lifelong laborer, blending logic with a sharp wit. Wyatt’s work captures the struggles and triumphs of everyday Americans, offering readers a fresh perspective grounded in traditional values, individual freedom, and an unwavering love for his country.



Trending